You might know you need to conduct drug metabolism and pharmacokinetic (DMPK) analysis, but which tests are right for your project? And are you doing them at the right time? When building your preclinical strategy, these questions matter—and that’s true now more than ever, as new drug classes and targets emerge.
September 30, 2020
Expanding Access to CART Therapies: TD2 Oncology Featured in SCRS inFocus
In June 2025, the FDA announced a major shift in regulatory guidance: the elimination of Risk Evaluation and Mitigation Strategy (REMS) requirements ...
The Rise of Humanized Mouse Models in Oncology: What Drug Developers Need to Know
Traditional mouse models remain a cornerstone of preclinical oncology research. Syngeneic and xenografts mouse models continue to play a critical ...
Flow Cytometry User Groups And The Relaunch Of The NWFCS
By Jennifer J. Stewart, PhD
Get Started
Contact Us Today!
If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.
